MA40737A - Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 - Google Patents

Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1

Info

Publication number
MA40737A
MA40737A MA040737A MA40737A MA40737A MA 40737 A MA40737 A MA 40737A MA 040737 A MA040737 A MA 040737A MA 40737 A MA40737 A MA 40737A MA 40737 A MA40737 A MA 40737A
Authority
MA
Morocco
Prior art keywords
determinants
immunotherapy
blocked
cancer response
cancer
Prior art date
Application number
MA040737A
Other languages
English (en)
Inventor
Timothy A Chan
Matthew D Hellman
Naiyer A Rizvi
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MA40737A publication Critical patent/MA40737A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
MA040737A 2014-11-21 2015-11-22 Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 MA40737A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083088P 2014-11-21 2014-11-21
US201562132381P 2015-03-12 2015-03-12

Publications (1)

Publication Number Publication Date
MA40737A true MA40737A (fr) 2017-07-04

Family

ID=56014697

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040737A MA40737A (fr) 2014-11-21 2015-11-22 Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1

Country Status (9)

Country Link
US (3) US20180291074A1 (fr)
EP (1) EP3220950A4 (fr)
JP (3) JP7173733B2 (fr)
CN (2) CN114672559A (fr)
AU (2) AU2015349644B2 (fr)
CA (1) CA2968059A1 (fr)
HK (1) HK1244440A1 (fr)
MA (1) MA40737A (fr)
WO (1) WO2016081947A2 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104479018B (zh) 2008-12-09 2018-09-21 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
JP6920989B2 (ja) 2014-10-29 2021-08-18 ファイヴ プライム セラピューティクス インク がんのための併用療法
MA40737A (fr) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
IL259931B2 (en) 2015-12-16 2024-02-01 Gritstone Bio Inc Identification of neo-antigens, preparation, and use
CN109196121B (zh) * 2016-02-29 2022-01-04 基因泰克公司 用于癌症的治疗和诊断方法
JP2019509282A (ja) 2016-02-29 2019-04-04 ファウンデーション・メディシン・インコーポレイテッド 癌の治療方法
JP6918816B2 (ja) * 2016-03-01 2021-08-18 ノース カロライナ ステート ユニバーシティ マイクロニードルパッチ支援送達による強化されたがん免疫療法
US11318185B2 (en) 2016-03-02 2022-05-03 Toray Industries, Inc. Immunogenic peptides of SCD1 protein
CA3024508A1 (fr) 2016-05-27 2017-11-30 Agenus Inc. Anticorps anti-tim-3 et leurs methodes d'utilisation
JP6910653B2 (ja) * 2016-07-01 2021-07-28 国立大学法人東北大学 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法
KR20190038935A (ko) 2016-08-25 2019-04-09 난토믹스, 엘엘씨 면역요법 마커들 및 그 용도들(immunotherapy markers and uses therefor)
TWI775781B (zh) * 2016-10-06 2022-09-01 美商建南德克公司 癌症之治療性及診斷性方法
CA3039402A1 (fr) 2016-10-07 2018-04-12 Omniseq, Inc. Procedes et systemes pour determiner des therapies personnalisees
US20190369096A1 (en) * 2017-01-13 2019-12-05 Nantbio, Inc. Validation of neoepitope-based treatment
EP3576781B9 (fr) * 2017-01-18 2024-03-06 Icahn School of Medicine at Mount Sinai Néoantigènes et leurs utilisations dans le traitement du cancer
WO2018144775A1 (fr) 2017-02-01 2018-08-09 Modernatx, Inc. Compositions thérapeutiques immunomodulatrices d'arnm codant pour des peptides de mutation d'activation d'oncogènes
ES2885178T3 (es) * 2017-02-06 2021-12-13 Novartis Ag Método para la predicción de respuesta a la inmunoterapia
US20190360051A1 (en) * 2017-02-17 2019-11-28 Stichting Vumc Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets
KR20190142767A (ko) * 2017-03-20 2019-12-27 제노세아 바이오사이언스, 인코퍼레이티드 치료 방법
AU2018243754A1 (en) * 2017-03-31 2019-10-17 Bristol-Myers Squibb Company Methods of treating tumor
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
JP2020527351A (ja) * 2017-07-21 2020-09-10 ジェネンテック， インコーポレイテッド がんの治療法及び診断法
CN111148996A (zh) * 2017-07-28 2020-05-12 百时美施贵宝公司 用于检查点抑制剂的预测性外周血生物标志物
JP2020535119A (ja) * 2017-09-13 2020-12-03 ファイヴ プライム セラピューティクス インク 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ−１抗体組合せ併用療法
WO2019055860A1 (fr) * 2017-09-15 2019-03-21 The Texas A&M University System Méthodes d'amélioration de l'immunothérapie dans le traitement du cancer
CA3076894A1 (fr) 2017-09-25 2019-03-28 Memorial Sloan Kettering Cancer Center Fardeau de mutations et immunotherapie des points de controle
CA3076918A1 (fr) * 2017-10-02 2019-04-11 Curematch, Inc. Procede de prediction de l'antigenicite et/ou de l'immunogenicite d'un neo-peptide derive d'une tumeur, a l'aide de motifs de signature mutationnelle
CN111465989A (zh) 2017-10-10 2020-07-28 磨石肿瘤生物技术公司 使用热点进行的新抗原鉴别
US11810672B2 (en) 2017-10-12 2023-11-07 Nantomics, Llc Cancer score for assessment and response prediction from biological fluids
US20200239577A1 (en) 2017-10-15 2020-07-30 Bristol-Myers Squibb Company Methods of treating tumor
CA3079253A1 (fr) 2017-11-03 2019-05-09 Guardant Health, Inc. Normalisation de la charge de mutation tumorale
AU2018367925A1 (en) * 2017-11-17 2020-07-02 Gmdx Co Pty Ltd Systems and methods for predicting the efficacy of cancer therapy
JP2021503897A (ja) 2017-11-22 2021-02-15 グリットストーン オンコロジー インコーポレイテッド 新生抗原のためのジャンクションエピトープ提示の低減
CN110770838B (zh) * 2017-12-01 2023-12-19 Illumina公司 用于确定体细胞突变克隆性的方法和系统
EP3788173B1 (fr) * 2018-05-03 2023-11-29 F. Hoffmann-La Roche AG Marqueur de substitution et procédé de mesure de charge de mutation de tumeur
JP2021522298A (ja) * 2018-05-04 2021-08-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌治療のためのＰＤ−１／ＰＤ−Ｌ１、ＴＧＦβおよびＤＮＡ−ＰＫの同時阻害
SG11202100344WA (en) 2018-07-23 2021-02-25 Guardant Health Inc Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
WO2020021119A1 (fr) 2018-07-27 2020-01-30 F. Hoffmann-La Roche Ag Procédé de surveillance de l'efficacité d'immunothérapie de patients atteints d'un cancer
EP3845236A4 (fr) * 2018-08-29 2022-07-27 Tokyo Metropolitan Institute of Medical Science Agent antitumoral ciblant un substrat de tyrosine kinase régulée par hgf (hgs)
JP2021535489A (ja) 2018-08-31 2021-12-16 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａにおけるマイクロサテライト不安定性の検出
JP2022513068A (ja) * 2018-11-15 2022-02-07 パーソナル ゲノム ダイアグノスティクス インコーポレイテッド 免疫療法で治療されたがん患者の応答の予測を改善する方法
US20200190598A1 (en) * 2018-12-12 2020-06-18 Medimmune, Llc Blood-based tumor mutation burden predicts overall survival in nsclc
WO2020252456A1 (fr) * 2019-06-14 2020-12-17 The Trustees Of Columbia University In The City Of New York Inhibiteurs de nt5c2 pour le traitement de la leucémie lymphoblastique aiguë résistante à la chimiothérapie
GB202003669D0 (en) * 2020-03-13 2020-04-29 Univ Oxford Innovation Ltd Method for identifying neo-antigens
EP4143345A1 (fr) 2020-04-28 2023-03-08 Genentech, Inc. Procédés et compositions pour l'immunothérapie du cancer du poumon non à petites cellules
WO2022099004A1 (fr) * 2020-11-06 2022-05-12 The General Hospital Corporation Procédés pour caractériser des échantillons biologiques
WO2022235482A1 (fr) * 2021-05-03 2022-11-10 Rutgers, The State University Of New Jersey Immunothérapie pour une maladie intestinale inflammatoire et/ou un cancer
CN113030475B (zh) * 2021-05-25 2021-08-10 泛肽生物科技(浙江)有限公司 一种基于细胞线粒体质量评估的t细胞pd-1检测方法
CN113355424B (zh) * 2021-07-14 2022-03-25 江苏先声医学诊断有限公司 Pcdh11x突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033497A1 (en) 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
CN102713606A (zh) * 2009-11-13 2012-10-03 无限制药股份有限公司 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
ES2608475T3 (es) * 2010-04-13 2017-04-11 Celldex Therapeutics, Inc. Anticuerpos que se unen a cd27 humana y usos de los mismos
EP2569633B1 (fr) * 2010-05-14 2016-02-10 The General Hospital Corporation Compositions et procédés d'identification de néoantigènes spécifiques à une tumeur
SI2844282T1 (sl) 2012-05-04 2019-08-30 Pfizer Inc. S prostato povezani antigeni in na cepljenju osnovan imunoterapevtski režim zdravljenja
AU2013323368B2 (en) 2012-09-28 2019-03-21 The University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
KR20160102314A (ko) * 2014-01-02 2016-08-29 메모리얼 슬로안-케터링 캔서 센터 면역 치료요법에 대한 암 반응의 결정인자
WO2016077553A1 (fr) * 2014-11-13 2016-05-19 The Johns Hopkins University Blocage de point de contrôle et instabilité des microsatellites
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
CA3076894A1 (fr) * 2017-09-25 2019-03-28 Memorial Sloan Kettering Cancer Center Fardeau de mutations et immunotherapie des points de controle

Also Published As

Publication number Publication date
JP2020196732A (ja) 2020-12-10
US20200040049A1 (en) 2020-02-06
EP3220950A2 (fr) 2017-09-27
US20180291074A1 (en) 2018-10-11
CN114672559A (zh) 2022-06-28
US10993998B2 (en) 2021-05-04
CN107206064A (zh) 2017-09-26
WO2016081947A3 (fr) 2016-07-07
WO2016081947A4 (fr) 2016-09-09
AU2021215099A1 (en) 2021-08-26
AU2015349644A1 (en) 2017-06-15
EP3220950A4 (fr) 2018-08-29
CN107206064B (zh) 2021-12-21
CA2968059A1 (fr) 2016-05-26
US20210308241A1 (en) 2021-10-07
HK1244440A1 (zh) 2018-08-10
JP7173733B2 (ja) 2022-11-16
AU2015349644B2 (en) 2021-08-19
WO2016081947A2 (fr) 2016-05-26
JP2023055625A (ja) 2023-04-18
JP2018502828A (ja) 2018-02-01

Similar Documents

Publication Publication Date Title
MA40737A (fr) Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
SG11201605432RA (en) Determinants of cancer response to immunotherapy
MA43258A (fr) Liants pd1/ctla4
DK3204417T3 (da) Cd73-blokering
DK3186244T3 (da) Dioxolananaloger af uridin til behandling af cancer
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3175012T3 (da) Forbedret aktivering af selvpassiverende metaller
DE112015003457A5 (de) Al-Gusslegierung
HK1250719A1 (zh) 脫氧糖胺的合成
DK3201559T3 (da) Patronhylster
DK3397352T3 (da) Antiperspirantsammensætninger
DK3253407T3 (da) Brug af hla-b27-homodimere til kræftbehandling
DK3273821T3 (da) Tilpasseligt smykke
HK1258143A1 (zh) 和厚朴酚的改進的合成
FR3040595B3 (fr) Parasol suspendu demontable
ES1137506Y (es) Helice reductora de perdidas
FR3023260B1 (fr) Ensemble propulsif d'aeronef
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
EP3516081A4 (fr) Déterminants de la réponse d'un cancer à l'immunothérapie
DK3230300T3 (da) Inhibitorer til inhibering af tumor metastase
MC200163B1 (fr) Revêtement pour la protection des supports métalliques
IT201700081473A1 (it) Prevenzione mareggiate
FI11432U1 (fi) Kantosuoja
IT201700010606A1 (it) GenialCombi di Moscarelli
IT201600129753A1 (it) Struttura di calcio-balilla